Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ENTX · against 465 other Healthcare companies of similar size
Ranked #303 of 466 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score164 peers with a valuation score of 0–9, including ENTX · Click a bar to see the companies
Mainly because of its earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
| Metric | ENTX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 454 reported | -11.8% | 0.6% | 20% | 30% | |
| EBITDA yieldHigher is better · 471 reported | -2.8% | 3.6% | 27% | 50% | |
| Free cash flow yieldHigher is better · 199 reported | -2.1% | -5.8% | 60% | 20% | |
| Book yieldHigher is better · 462 reported | 4.8% | 47.5% | 7% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 303 | 399M USD | 8 | 32 | |
| 303 | 4.6B SEK (≈$462M) | 8 | 37 | |
| 303 | 301M USD | 8 | ||
| 303 | 302M USD | 8 | 17 | |
| 303 | 530M USD | 8 | 23 | |
| 303 | 487M USD | 8 | 29 | |
| 303 | 455M USD | 8 | 36 | |
| 303 | 486M USD | 8 | 16 | |
| 303 | 551M USD | 8 | 27 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score